دورية أكاديمية
[Using deltalicin for the treatment of patients with diabetic retinopathy].
| العنوان: | [Using deltalicin for the treatment of patients with diabetic retinopathy]. |
|---|---|
| المؤلفون: | Kresiun NV, Godlevskiĭ LS |
| المصدر: | Eksperimental'naia i klinicheskaia farmakologiia [Eksp Klin Farmakol] 2014; Vol. 77 (12), pp. 22-5. |
| نوع المنشور: | Clinical Trial; English Abstract; Journal Article |
| اللغة: | Russian |
| بيانات الدورية: | Publisher: Izd-vo Meditsina Country of Publication: Russia (Federation) NLM ID: 9215981 Publication Model: Print Cited Medium: Print ISSN: 0869-2092 (Print) Linking ISSN: 08692092 NLM ISO Abbreviation: Eksp Klin Farmakol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Moskva : Izd-vo Meditsina |
| مواضيع طبية MeSH: | Delta Sleep-Inducing Peptide/*therapeutic use , Diabetic Retinopathy/*drug therapy , Neurotransmitter Agents/*therapeutic use, Adult ; Delta Sleep-Inducing Peptide/administration & dosage ; Diabetic Retinopathy/physiopathology ; Evoked Potentials, Visual/drug effects ; Humans ; Neurotransmitter Agents/administration & dosage ; Photic Stimulation ; Treatment Outcome |
| مستخلص: | The characteristics of visual evoked potential (VEP) have been investigated in a group of 15 healthy volunteers (aged 31.7 ± 3.6 years) and 30 insulin-dependent patients (aged 32.1 ± 4.0 years) with diabetes mellitus, among which 15 patients suffered from diabetic retinopathy and 15 patients had no retinopathy. An increase in the latent period along with reduction of the VEP amplitude after photostress action upon the macular part of retina have been observed in patients with diabetes, these effects were more pronounced in the subgroup with retinopathy. The restoration of VEP characteristics in 73.5 ± 3.3 s from the moment of photostress was observed in the control group, while this index in both subgroups of diabetic patients without and with retinopathy was 88.7 ± 5.9 and 137.2 ± 11.3 s, respectively. Treatment with deltalicin (daily dose of 0.0003 g of delta sleep-inducing peptide intranasally for two months) decreased the latent period and led to less pronounced depression of VEP amplitude in patients with diabetic retinopathy, and reduced the period of restoration of VEP characteristics to 95.1 ± 6.8 s. |
| المشرفين على المادة: | 0 (Neurotransmitter Agents) 69431-45-4 (Delta Sleep-Inducing Peptide) |
| تواريخ الأحداث: | Date Created: 20150306 Date Completed: 20150910 Latest Revision: 20150305 |
| رمز التحديث: | 20221213 |
| PMID: | 25739189 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0869-2092 |
|---|